Cardiovascular Disease

Lifestyle or medical therapy in prediabetes to reduce later cardiovascular events in type 2 diabetes may seem wise, yet little evidence demonstrates such strategies make a difference, according to a speaker.

The increased risks for cardiovascular disease conferred by diabetes are greater for women than for men, but the newer diabetes drug classes reduce those risks similarly for both sexes, according to a speaker.

Hyperglycemia is associated with the presence of multiple cardiac antibody types among people with type 1 diabetes, suggesting a novel mechanism for increased cardiovascular risk specific to the disease, according to a speaker.

Despite warnings about health risks associated with sugar-sweetened beverages, greater efforts are needed to decrease their consumption in the U.S., according to a speaker.

Vitamin K supplementation showed no effect on vascular stiffness or other markers of vascular health in patients with chronic kidney disease, according to a randomized controlled trial.

A study of patients with type 2 diabetes demonstrated those who had an increased progression of chronic kidney disease, as measured by eGFR, also had a higher likelihood of experiencing major adverse cardiovascular events.

Cardiologists can use SGLT2 inhibitors and GLP-1 receptor agonists to help reduce risk for major adverse CV events in patients with type 2 diabetes, according to an expert consensus decision pathway from the American College of Cardiology.

There is no documented benefit of cannabis use for CVD prevention or treatment, according to a scientific statement from the American Heart Association.

Healio and Cardiology Today have compiled a list of the most-read articles of July 2020.

Women younger than 50 years with polycystic ovary syndrome were at elevated risk for CVD compared with younger women without it, according to a research letter published in the European Journal of Preventive Cardiology.